2024-10-01 - Analysis Report
## Eli Lilly and Co. (LLY) Stock Analysis

**1. Performance Comparison and Divergence:**

Eli Lilly and Co. (LLY) has significantly outperformed the S&P 500 (VOO) over the period analyzed. The cumulative return for LLY is 848.17%, compared to 133.28% for the S&P 500. This results in a divergence of 714.89%, which is 88.83% of the maximum historical divergence between the two. This means LLY's performance has been remarkably strong relative to the broader market.

**2. Recent Price Movements:**

The current price of LLY is $880.22. The stock is trading below its recent moving averages, indicating potential downward pressure.  

* 5-day moving average: $910.92
* 20-day moving average: $919.26
* 60-day moving average: $898.76

**3. Technical Indicators:**

* **RSI (Relative Strength Index):** 40.07. This suggests the stock is currently in oversold territory, implying potential for a rebound.
* **PPO (Percentage Price Oscillator):** -0.48. This indicates bearish momentum in the short term. 
* **Delta_Previous_Relative_Divergence:** -9.24. This indicates a recent decline in the stock's relative strength.
* **Expected Return:** 6.94%. This is the projected maximum 5-year return on investment based on the current price and historical data.

**4. Recent Earnings and Outlook:**

Eli Lilly and Co. has consistently delivered strong earnings growth over the past few quarters. The most recent earnings report showed earnings per share (EPS) of $3.29, exceeding analysts' expectations. The company also reported strong revenue growth, with $11.30 billion in revenue.

| Date       | EPS   | Revenue        |
|------------|-------|----------------|
| 2024-08-08 | $3.29 | $11.30 B$       |
| 2024-04-30 | $2.49 | $8.77 B$       |
| 2023-11-02 | -$0.06 | $9.50 B$       |
| 2023-08-08 | $1.96 | $8.31 B$       |
| 2024-08-08 | $1.96 | $8.31 B$       | 

Analysts remain optimistic about Eli Lilly's future prospects, driven by strong growth in its core diabetes and oncology businesses, along with the potential of its new Alzheimer's drug.

**5. News and Recent Issues:**

* **Positive Market Sentiment:** According to FINBOLD, the market sentiment for Eli Lilly is positive, with a majority of analysts recommending a "buy" rating.
* **Strong Performance Highlights:** The company has consistently delivered strong financial performance, exceeding analysts' expectations in recent quarters. This has boosted investor confidence in the stock.
* **Alzheimer's Drug Potential:** Eli Lilly's experimental Alzheimer's drug, Donanemab, has shown promising results in clinical trials. This is considered a major growth driver for the company in the coming years.

**6. Overall Analysis:**

Eli Lilly and Co. (LLY) is a strong performer with a strong track record of growth and a bright future outlook. The stock has significantly outperformed the market and continues to show positive financial results.  While recent price movements suggest potential downward pressure, the company's strong fundamentals and growth prospects make it a compelling investment opportunity.

**7. English Report:**

Eli Lilly and Co. (LLY) is a global pharmaceutical company headquartered in Indianapolis, Indiana. The company specializes in the research, development, manufacturing, and marketing of pharmaceutical products. Its portfolio includes a wide range of medications, including treatments for diabetes, oncology, autoimmune disorders, and neurology.

**1. Performance Comparison and Divergence:**

Eli Lilly and Co. (LLY) has outperformed the S&P 500 (VOO) by a substantial margin, with a cumulative return of 848.17% compared to 133.28% for the S&P 500. This significant divergence of 714.89%, representing 88.83% of the maximum historical difference, highlights LLY's exceptional performance relative to the broader market.

**2. Recent Price Movements:**

LLY is currently trading at $880.22. The stock price is below its recent moving averages, indicating potential downward pressure. 

* 5-day moving average: $910.92
* 20-day moving average: $919.26
* 60-day moving average: $898.76

**3. Technical Indicators:**

* **RSI (Relative Strength Index):** 40.07. This reading suggests the stock is in oversold territory, potentially indicating a short-term rebound.
* **PPO (Percentage Price Oscillator):** -0.48. This negative value points to bearish momentum in the short term.
* **Delta_Previous_Relative_Divergence:** -9.24. The negative value indicates a recent decrease in the stock's relative strength.
* **Expected Return:** 6.94%. This represents the projected maximum 5-year return on investment based on the current price and historical data.

**4. Recent Earnings and Outlook:**

Eli Lilly has consistently delivered strong earnings growth over the past several quarters. The most recent earnings report showed earnings per share (EPS) of $3.29, surpassing analysts' expectations. The company also reported strong revenue growth, reaching $11.30 billion in revenue.

| Date       | EPS   | Revenue        |
|------------|-------|----------------|
| 2024-08-08 | $3.29 | $11.30 B$       |
| 2024-04-30 | $2.49 | $8.77 B$       |
| 2023-11-02 | -$0.06 | $9.50 B$       |
| 2023-08-08 | $1.96 | $8.31 B$       |
| 2024-08-08 | $1.96 | $8.31 B$       | 

Analysts remain optimistic about Eli Lilly's future prospects, driven by strong growth in its core diabetes and oncology businesses, and the potential of its new Alzheimer's drug.

**5. News and Recent Issues:**

* **Positive Market Sentiment:** According to FINBOLD, the market sentiment for Eli Lilly is positive, with a majority of analysts recommending a "buy" rating.
* **Strong Performance Highlights:** The company has consistently delivered strong financial performance, exceeding analysts' expectations in recent quarters. This has boosted investor confidence in the stock.
* **Alzheimer's Drug Potential:** Eli Lilly's experimental Alzheimer's drug, Donanemab, has shown promising results in clinical trials. This is considered a major growth driver for the company in the coming years.

**6. Overall Analysis:**

Eli Lilly and Co. (LLY) is a strong performer with a solid track record of growth and a bright future outlook. The stock has significantly outperformed the market and continues to show positive financial results.  While recent price movements suggest potential downward pressure, the company's strong fundamentals and growth prospects make it a compelling investment opportunity. 
